Format

Send to:

Choose Destination
See comment in PubMed Commons below
Trends Mol Med. 2012 Mar;18(3):173-81. doi: 10.1016/j.molmed.2012.01.001. Epub 2012 Feb 17.

New and future immunomodulatory therapy in type 1 diabetes.

Author information

  • 1Department of Immunobiology, Yale University, New Haven, CT 06511, USA.

Abstract

Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting β cells of the pancreas and requires lifelong insulin treatment. The effects of chronic hyperglycemia - the result of insulin deficiency - include secondary endorgan complications. Over the past two decades our increased understanding of the pathogenesis of this disease has led to the development of new immunomodulatory treatments. None have yet received regulatory approval, but this report highlights recent progress in this area.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PMID:
22342807
[PubMed - indexed for MEDLINE]
PMCID:
PMC3586241
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk